Quick Answer
CORCEPT THERAPEUTICS INC reported Cash and Equivalents of $120.50 million for fiscal year 2025.
CORCEPT THERAPEUTICS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $120.50M | -5.6% |
| 2024 | $127.67M | -5.8% |
| 2023 | $135.55M | +104.4% |
| 2022 | $66.33M | -14.5% |
| 2021 | $77.62M | +1.9% |
| 2020 | $76.19M | +143.7% |
| 2019 | $31.27M | -24.9% |
| 2018 | $41.62M | +34.0% |
| 2017 | $31.06M | -39.7% |
| 2016 | $51.54M | +27.5% |
| 2015 | $40.44M | +66.8% |
| 2014 | $24.25M | -55.8% |
| 2013 | $54.88M | -41.0% |
| 2012 | $93.03M | +134.7% |
| 2011 | $39.63M | +61.3% |
| 2010 | $24.58M | +3.0% |
| 2009 | $23.87M | +62.2% |
| 2008 | $14.72M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $125.14M | -8.9% | +21.8% |
| June 30, 2025 | $102.75M | -20.1% | +14.4% |
| March 31, 2025 | $89.82M | -40.0% | -29.6% |
| December 31, 2024 | $127.67M | -5.8% | -7.0% |
| September 30, 2024 | $137.29M | +22.8% | +6.8% |
| June 30, 2024 | $128.59M | -25.4% | -14.1% |
| March 31, 2024 | $149.75M | -50.1% | +10.5% |
| December 31, 2023 | $135.55M | +104.4% | +21.2% |
- CORCEPT THERAPEUTICS INC showed a decrease of -5.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, CORCEPT THERAPEUTICS INC’s cash and equivalents has grown by 718.8% (from $14.72 million to $120.50 million).
- The most recent figure is from CORCEPT THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: